01322nas a2200433   4500000000100000000000100001000000100002008004100003653001100044653003100055653001100086653000900097653005800106653005200164653001000216653001600226653001900242653003500261653001900296653006400315653004100379653003000420653003000450653005100480653002100531653003700552653001500589653004000604100002000644700001300664700001600677700001400693700001400707700002200721245010900743250001500852490000700867020001400874       2025                            d10aHumans10a*Metformin/therapeutic use10aFemale10aMale10a*Antipsychotic Agents/therapeutic use/adverse effects10aPrimary Health Care/statistics & numerical data10aAdult10aMiddle Aged10aUnited Kingdom10a*Mental Disorders/drug therapy10aCohort Studies10a*Practice Patterns, Physicians'/statistics & numerical data10a*Hypoglycemic Agents/therapeutic use10a*Weight Gain/drug effects10aDrug Therapy, Combination10aDrug Prescriptions/statistics & numerical data10aadult psychiatry10adata interpretation, statistical10aPsychiatry10aSchizophrenia & psychotic disorders1 aFarache Trajano1 aJ. Hayes1 aN. Launders1 aN. Davies1 aD. Osborn1 aA. Richards-Belle00aCo-prescription of metformin and antipsychotics in severe mental illness: a UK primary care cohort study  a2025/04/030 v28  a2755-9734